SynthesisFrontiers in immunology2026
Combination therapy with anti-PD-1 antibody, radiotherapy, and tyrosine kinase inhibitor for unresectable primary ectopic hepatocellular carcinoma: a case report with genomic profiling and literature review.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Ectopic hepatocellular carcinoma (EHCC) is an exceedingly rare malignancy characterized by its occurrence outside the liver without a detectable intrahepatic primary tumor. Owing to its rarity and the absence of standardized management guidelines, the diagnosis and treatment of EHCC pose significant challenges. Methods: We report a case of unresectable, multifocal EHCC managed by a multidisciplinary team (MDT). Comprehensive molecular profiling, including whole-exome sequencing (WES) and RNA sequencing (RNA-seq), was performed to characterize the tumor's genetic and transcriptomic landscape. A systematic literature review of EHCC case reports in the PubMed database was also conducted. Results: A patient in his sixties was diagnosed with unresectable, multifocal EHCC localized within the abdominal cavity. The diagnosis was confirmed by laparoscopic biopsy and histopathological examination, which revealed hepatocellular carcinoma with fatty metaplasia, corroborated by positive immunohistochemical staining. Comprehensive genomic analysis using RNA-seq and WES identified key molecular features potentially involved in EHCC pathogenesis. Guided by the MDT, the patient received a multimodal regimen comprising lenvatinib (8 mg once daily), camrelizumab (200 mg every two weeks; an anti-PD-1 antibody), and stereotactic body radiotherapy (SBRT) targeting residual abdominal lesions. The patient achieved a progression-free survival (PFS) of 27 months and an overall survival (OS) of 30 months. A systematic review of 55 reported EHCC cases provided a comprehensive overview of the disease's demographic, clinical, management, and prognostic characteristics. Conclusion: This study provides the molecular profiling of an EHCC case, offering descriptive insights into its genomic and transcriptomic landscape. Furthermore, the favorable clinical outcome associated with the combination therapy of lenvatinib, camrelizumab, and SBRT suggests the potential value of this multimodal strategy, indicating a potential therapeutic approach for future cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.